Spark Biomedical closed a $15 million Series A round to support its bioelectronic neurostimulation technologies.
Wave Ventures led the financing round, which also received support from Pathway to Cures. The company plans to use funds to accelerate the development of its bioelectronic treatments. Funding supports the core areas of its business: neurological health, hemostasis and women’s health.
Related: Transverse Medical raises $10M in Series B2 round
Spark Biomedical harnesses the body’s natural response to electrical signals to deliver targeted relief without invasive procedures or pharmaceuticals. It activates the central nervous system to modulate pathways, reduce discomfort and support physiological balance. This results in non-invasive, drug-free support for a range of conditions.
“Completing our Series A fundraise marks a pivotal moment for Spark Biomedical as we scale our bioelectronic medicine platform,” says Spark Biomedical CEO and Co-founder, Daniel Powell. “This investment empowers us to advance the development of non-invasive neurostimulation therapies that address significant unmet clinical needs. Our vision is to redefine how neurological conditions are treated — not with chemicals, but with precisely targeted bioelectric solutions.”
Spark’s current FDA-cleared wearable neurostimulation solution, for opioid withdrawal, Sparrow Ascent, is improving and saving lives every day, according to the company’s website.
